Trial · NCT00459342

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00459342, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2013-12-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer. Trials, record NCT00459342. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00459342

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT number: NCT00459342
Status: Completed
Phases: Phase 2
Enrollment: 35 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: dasatinib
First posted: 2007-04-11
Last updated: 2019-03-05
Results first posted: 2013-12-24

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR))	12 weeks	Objective response defined as participants with Complete Response (CR) or Partial Response (PR) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. RECIST definitions are Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Response measured by tumor size on computed tomography scans and by metabolic activity on positron emission tomography scans.
Primary	Progression-free Survival (PFS)	Time from start of treatment to time of progression or death, assessed at 2 months	Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death.
Other	Time to Progression (TTP)	Time from start of treatment to time of progression or death, assessed radiographically every 6 weeks
Other	Epidermal Growth Factor Receptor (EGFR) Mutational Status	Baseline
Other	Epidermal Growth Factor Receptor (EGFR) Copy Number	Baseline
Other	Phospho-Src (pSrc) Expression	Baseline

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR))	12 weeks	Of the 34 eligible study participants enrolled, four participants were not evaluable for response.	participants	NUMBER
PRIMARY	Progression-free Survival (PFS)	Time from start of treatment to time of progression or death, assessed at 2 months	Four participants were not evaluable for response.	months	MEDIAN
OTHER_PRE_SPECIFIED	Time to Progression (TTP)	Time from start of treatment to time of progression or death, assessed radiographically every 6 weeks	Seven patients discontinued dasatinib because of toxicity or unrelated medical problems (i.e., not progression) and are not evaluable for progression.	days	MEAN
OTHER_PRE_SPECIFIED	Epidermal Growth Factor Receptor (EGFR) Mutational Status	Baseline		participants	NUMBER
OTHER_PRE_SPECIFIED	Epidermal Growth Factor Receptor (EGFR) Copy Number	Baseline		participants	NUMBER
OTHER_PRE_SPECIFIED	Phospho-Src (pSrc) Expression	Baseline		participants	NUMBER

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR))	Dasatinib	Partial Remission	1		participants
Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR))	Dasatinib	Stable Disease	12		participants
Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR))	Dasatinib	Progressive Disease	17		participants
Progression-free Survival (PFS)	Dasatinib		1.36	95% Confidence Interval 0.16 to 17.2	months
Time to Progression (TTP)	Dasatinib		92	Standard Deviation 107	days
Epidermal Growth Factor Receptor (EGFR) Mutational Status	Dasatinib	EGFR mutant	9		participants
Epidermal Growth Factor Receptor (EGFR) Mutational Status	Dasatinib	EGFR wild type	22		participants
Epidermal Growth Factor Receptor (EGFR) Mutational Status	Dasatinib	EGFR not tested	3		participants
Epidermal Growth Factor Receptor (EGFR) Copy Number	Dasatinib	EGFR amplfied	3		participants
Epidermal Growth Factor Receptor (EGFR) Copy Number	Dasatinib	EGFR not amplified	17		participants

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Dasatinib	35
Overall Study	COMPLETED	Dasatinib	34
Overall Study	NOT COMPLETED	Dasatinib	1

Source ClinicalTrials.gov

Adverse events105

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain	General disorders	Dasatinib	2	35	2
other	Alanine aminotransferase increased	Blood and lymphatic system disorders	Dasatinib	3	35	3
other	Allergic rhinitis	Immune system disorders	Dasatinib	2	35	2
other	Alopecia	Skin and subcutaneous tissue disorders	Dasatinib	1	35	1
other	Anal hemorrhage	Gastrointestinal disorders	Dasatinib	1	35	1
other	Anemia	Blood and lymphatic system disorders	Dasatinib	6	35	9
other	Anorexia	Metabolism and nutrition disorders	Dasatinib	16	35	17
other	Anxiety	Psychiatric disorders	Dasatinib	6	35	7
other	Arthritis	Musculoskeletal and connective tissue disorders	Dasatinib	2	35	2
other	Aspartate aminotransferase increased	Endocrine disorders	Dasatinib	3	35	3

1 to 10 of 105Source ClinicalTrials.gov

See all 105 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dasatinib
Total, other adverse events	Dasatinib	34	35
Total, serious adverse events	Dasatinib	25	35

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA016672	The University of Texas MD Anderson Cancer Center Support Grant (CCSG)	KOONG, ALBERT	UNIVERSITY OF TX MD ANDERSON CAN CTR	NATIONAL CANCER INSTITUTE	1985 to 2026

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00459342

GET https://conductscience.org/api/trials/v1/NCT00459342/events?page=2

API reference For AI assistants